C-Path’s TRxA Announces its 2024 Global Request for Proposals from Academic Investigators Working to Advance Drug Development Projects


TUCSON, Ariz, January 22, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe. Continue reading

C-Path to Lead New Task Force Aimed at Accelerating Drug Development for Mitochondrial and Inherited Metabolic Diseases

TUCSON, Ariz., January 11, 2024 — Critical Path Institute (C-Path) today announced the launch of a task force focused on accelerating drug development for mitochondrial and inherited metabolic diseases. The task force will lay the groundwork for specific solutions, offering valuable insights that aim to contribute to regulatory decision-making.Continue reading

C-Path Welcomes Mucopolysaccharidosis Clinical Trial Data Contribution from Children’s Hospital of Orange County into RDCA-DAP

TUCSON, Ariz., December 12, 2023 – C-Path (Critical Path Institute) is thrilled to announce a significant addition to its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). Children’s Hospital of Orange County (CHOC) has generously contributed clinical trial data related to mucopolysaccharidosis (MPS), reinforcing the power of collaboration in advancing rare disease research.Continue reading

C-Path’s Pioneering Neuroscience Workshop Transforms the Landscape of Neurological Disorder Therapies

TUCSON, Ariz., Nov. 9, 2023 – Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled “Transforming Drug Development for Neurological Disorders: Proceedings from a Multi-disease Area Workshop,” now published in Neurotherapeutics, The Journal of the American Society for Experimental Neurotherapeutics.Continue reading